z-logo
Premium
Clinical significance of MicoRNA‐155 expression in human breast cancer
Author(s) -
Chen Jian,
Wang BingChan,
Tang JinHai
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.22153
Subject(s) - medicine , breast cancer , oncology , mir 155 , cancer , stage (stratigraphy) , cancer research , microrna , biology , gene , paleontology , biochemistry
Background The aim of this study is to investigate clinical significance of miR‐155 expression in breast cancer. Methods TaqMan real‐time RT‐PCR was performed to detect miR‐155 expression in breast cancer tissues. The correlation of miR‐155 expression with clinicopathological factors and prognosis of breast cancer patients was analyzed. Then, the prognostic value of miR‐155 expression was analyzed by univariate and multivariate analyses. Moreover, the effect of miR‐155 expression on phenotypes of breast cancer cell was determined by antisense technology. Results The relative expression of miR‐155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR‐155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis ( P  = 0.012, 0.001, and 0.003, respectively). Kaplan–Meier survival analysis indicated that the disease‐free and overall survival rates of high miR‐155 group were significantly lower than those of low miR‐155 group ( P  = 0.038 and 0.029, respectively). Multivariate analysis showed that high miR‐155 expression was a poor prognostic factor ( P  = 0.009). Furthermore, antisense targeting miR‐155 could inhibit growth, induce cell arrest in G 0 /G 1 phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells. Conclusions MiR‐155 expression might be an independent prognostic factor and a therapeutic target for human breast cancer. J. Surg. Oncol. 2012; 106:260–266. © 2011 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here